Loading clinical trials...

A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy

A Single-Arm, Open-Label Clinical Study of iPSC-Derived Islet Cells for the Treatment of Diabetes Mellitus

NCT07464119•Peking University First Hospital

Summary

This is a single-arm, open-label clinical trial designed to assess the safety and therapeutic efficacy of iPSC-derived islet cell infusion in patients with diabetes mellitus.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects aged 18 years or older, of any sex.
•Duration of diabetes \> 5 years.
•Body mass index (BMI) 18-35 kg/m².
•Receiving insulin therapy.

Exclusion Criteria

•Presence of HIV infection , or active acute or chronic hepatitis infection (HBV or HCV), or Treponema pallidum infection.
•Active pulmonary tuberculosis or patients undergoing treatment for suspected tuberculosis.
•Uncontrolled systemic fungal, bacterial, viral, or other infections .
•Presence of severe diabetic complications.
•Presence of severe organic lesions in vital organs such as the heart, lungs, or brain.
•History of malignant tumors.

Locations (1)

Peking University First Hospital

Beijing, China

Key Dates

Start Date

March 16, 2026

Primary Completion Date

December 31, 2028

Completion Date

December 31, 2033

Last Updated

March 11, 2026

Enrollment

ESTIMATED participants

Conditions

Diabetes Mellitus

Interventions

iPSC-derived islet cell

BIOLOGICAL

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITING

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 11, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Genetic Studies of Insulin and Diabetes

Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Fasted Exercise Training in Type 1 Diabetes (FED-T1D)

Achieving Routine Intervention and Screening for Emotional Health